Clinical Trial for Anle138b

Clinical Trial for Anle138b
This week, the German biotech company, MODAG, announced that their first drug candidate for neurodegenerative conditions has started Phase I safety testing in humans. The drug, Anle138b, is being developed for Parkinson's and it has previously shown to rescue neurons in pre-clinical models of alpha synuclein-associated Parkinson's. Anle138b targets a protein called alpha-synuclein which is abundant in the healthy human ... read more
Source: The Cure Parkinson’s TrustPublished on 2019-12-19